In addition to small-molecule inhibitors, another LOXL2 inhibitor is the patented de primary amino-containing diazocynonane compound, which was tested in a transgenic mouse model of breast cancer and shown to availably reduce lung metastasis formation. The gene discussed is LOXL2; the disease is breast carcinoma.